OBJECTIVE: To explore the clinical effects of nimotuzumab combined with chemotherapy in the treatment of late @entity356 . METHODS: A total of 34 reoccurrence or metastatic @entity1 with late stage @entity356 who were confirmed by histopathology and/or cytology were selected and randomly divided into observational and control groups, of 17 cases each. @entity1 in the control group were treated with the standard DCF plan, while @entity1 in observational group additionally received nimotuzumab. The short-term and long-term efficacy and adverse reactions in the 2 groups were followed. RESULTS: The objective response rate (ORR) and disease control rate (DCR) were 64.7% (11/17) and 82.4% (14/17) in observational group and 25.0%(4/16) and 37.5%(6/16) in the control group(ORR and DCR between 2 groups,   2=5.2412, P=0.0221 and   2=6.9453, P=0.0084). The median progression-free survival (PFS) time and median overall survival (OS) time were 6.50 months and 12.50 months in observational group and 4.50 months and 8.25 months in the control group (P=0.0212; P=0.0255). The main @entity137 and side effects in the 2 groups were reduced leukocytes and hemoglobin, gastrointestinal reactions and hair loss and these were relieved after symptomatic treatment and nutrition support therapy. There were no differences in the occurrence of @entity137 and side effects between the 2 groups. CONCLUSIONS: Nimotuzumab combined with DCF plan is effective in treating late stage @entity356 . A larger scale study is now warranted for confirmation of the findings.

Clinical study of nimotuzumab combined with chemotherapy in the treatment of late stage XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'Patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxic'] @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric cancer']
@entity356 :: (MESH:D013274,Disease) :: ['gastric cancer']
